• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by GH Research PLC

    11/14/24 9:05:43 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GHRS alert in real time by email
    SC 13G/A 1 p24-3209sc13ga.htm GH RESEARCH PLC

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    GH Research PLC

    (Name of Issuer)
     

    Ordinary shares, nominal value $0.025 per share

    (Title of Class of Securities)
     

    G3855L106

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. G3855L10613G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Lynx1 Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,195,894

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,195,894

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,195,894

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.1%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. G3855L10613G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Weston Nichols

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,195,894

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,195,894

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,195,894

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.1%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. G3855L10613G/APage 4 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
       
     

    GH Research PLC (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.
       
     

    Joshua Dawson House, Dawson Street

    Dublin 2, Ireland D02RY95

     

    Item 2(a). Name of Person Filing.
       
      This statement is filed by:  

     

      (i)

    Lynx1 Capital Management LP (the “Investment Manager”), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the “Lynx1 Fund”), with respect to the Ordinary Shares (as defined in Item 2(d) below) directly held by the Lynx1 Fund; and

     

      (ii) Mr. Weston Nichols (“Mr. Nichols”), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the  Ordinary Shares directly held by the Lynx1 Fund.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein.

     

    Item 2(b). Address of Principal Business Office.
       
     

    Lynx1 Capital Management LP

    151 Calle de San Francisco

    Suite 200, PMB 1237

    San Juan, PR 00901-1607

     

    Weston Nichols

    c/o Lynx1 Capital Management LP

    151 Calle de San Francisco

    Suite 200, PMB 1237

    San Juan, PR 00901-1607

       
    Item 2(c). Place of Organization.
       
     

    Investment Manager – Delaware

    Mr. Nichols – United States of America

     

    CUSIP No. G3855L10613G/APage 5 of 7 Pages


     

    Item 2(d). Title of Class of Securities.
       
      Ordinary shares, nominal value $0.025 per share (the “Ordinary Shares”)

     

    Item 2(e). CUSIP Number.
       
      G3855L106

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) o

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

     

    CUSIP No. G3855L10613G/APage 6 of 7 Pages

     

    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

    The percentages set forth herein are calculated based upon 52,028,145 Ordinary Shares outstanding as of June 30, 2024, as reported in Exhibit 99.1 to the Report of Foreign Issuer on Form 6-K filed with the Securities and Exchange Commission on September 3, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      See Item 2. The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares reported herein.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. G3855L10613G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  November 14, 2024  
     

    Lynx1 capital management lp

    By: Lynx1 Capital Management GP LLC, its general partner

     

       
      By:  /s/ Weston Nichols
      Name:  Weston Nichols
      Title:    Sole Member
       
       
       
       
      /s/ Weston Nichols
      WESTON NICHOLS

     

     

    Get the next $GHRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHRS

    DatePrice TargetRatingAnalyst
    6/4/2025$25.00Overweight
    Cantor Fitzgerald
    3/13/2025$32.00Buy
    Guggenheim
    3/7/2025$31.00Outperform
    RBC Capital Mkts
    2/13/2025$14.00Overweight
    Cantor Fitzgerald
    8/16/2022$45.00Buy
    H.C. Wainwright
    6/16/2022$66.00Buy
    ROTH Capital
    7/20/2021Buy
    Stifel
    7/20/2021$35.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GHRS
    Financials

    Live finance-specific insights

    See more
    • GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

      Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no serious adverse events (SAE) were reported. There was no evidence of treatment-emergent suicidal ideation or behavior. As of January 22, 2025, no SAEs have been reported throughout the open

      2/3/25 7:00:10 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

      DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under "Events & Presentations" in the Investors section of GH Research PLC's website at ghres.com. About GH Research PLC GH

      1/31/25 4:01:35 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GH Research PLC

      SC 13G/A - GH Research PLC (0001855129) (Subject)

      11/14/24 5:46:11 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GH Research PLC

      SC 13G/A - GH Research PLC (0001855129) (Subject)

      11/14/24 9:05:43 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GH Research PLC

      SC 13G - GH Research PLC (0001855129) (Subject)

      2/16/24 4:57:41 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

      DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania will present clinical data from a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (

      5/15/25 7:00:00 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

      Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $315.3 million as of March 31, 2025 DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business. Business Updates GH001 in Patients with TRD Our multi-center, randomize

      5/8/25 7:00:03 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

      Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UKFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming t

      2/27/25 7:00:25 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    SEC Filings

    See more
    • SEC Form 6-K filed by GH Research PLC

      6-K - GH Research PLC (0001855129) (Filer)

      5/27/25 7:00:30 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GH Research PLC

      6-K - GH Research PLC (0001855129) (Filer)

      5/21/25 7:00:41 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by GH Research PLC

      SCHEDULE 13G/A - GH Research PLC (0001855129) (Subject)

      5/15/25 4:58:22 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on GH Research PLC with a new price target

      Cantor Fitzgerald resumed coverage of GH Research PLC with a rating of Overweight and set a new price target of $25.00

      6/4/25 8:19:53 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on GH Research PLC with a new price target

      Guggenheim initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $32.00

      3/13/25 7:38:21 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on GH Research PLC with a new price target

      RBC Capital Mkts initiated coverage of GH Research PLC with a rating of Outperform and set a new price target of $31.00

      3/7/25 7:25:01 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Leadership Updates

    Live Leadership Updates

    See more
    • GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

      DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin

      9/3/24 7:00:05 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

      DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise inv

      8/23/23 7:00:45 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care